For help on how to get the results you want, see our search tips.
1753 results
Medicine
Maximum residue limits Remove Maximum residue limits filter
Withdrawn applications Remove Withdrawn applications filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Summaries of opinion Remove Summaries of opinion filter
PIP decision type
PM: decision on the application for modification of an agreed PIP Remove PM: decision on the application for modification of an agreed PIP filter
W: decision granting a waiver in all age groups for all conditions or indications Remove W: decision granting a waiver in all age groups for all conditions or indications filter
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Temelimab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-002127-PIP01-17-M01, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Solution for infusion
Decision date: 12/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Fasinumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Pain
PIP number: EMEA-002059-PIP02-19-M01, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 12/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tralokinumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Dermatology
PIP number: EMEA-001900-PIP02-17-M05, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 11/08/2022, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Lactobacillus reuteri (IBP-9414)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology; Neonatology-Paediatric Intensive Care; Other
PIP number: EMEA-001895-PIP01-15-M01, Route(s) of administration: Gastroenteral use, Pharmaceutical form(s): Powder for oral suspension
Decision date: 11/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): ligelizumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Dermatology
PIP number: EMEA-001811-PIP02-15-M04, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection, Age-appropriate dosage form for parenteral use
Decision date: 11/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Anti-respiratory syncytial virus human IgG1κ monoclonal antibody (MEDI8897)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases; Vaccines
PIP number: EMEA-001784-PIP01-15-M03, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Solution for injection
Decision date: 11/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Kerendia, Finerenone
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Uro-nephrology
PIP number: EMEA-001623-PIP01-14-M04, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral (liquid or solid) dosage form
Decision date: 11/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Dermatology
PIP number: EMEA-001501-PIP01-13-M07, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 11/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Sirolimus
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Ophthalmology
PIP number: EMEA-001416-PIP01-12-M03, Route(s) of administration: Intravitreal use, Pharmaceutical form(s): Solution for injection
Decision date: 11/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Imbruvica, Ibrutinib
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-001397-PIP03-14-M06, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Capsule, hard
Decision date: 11/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Adynovi, rurioctocog alfa pegol
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001296-PIP01-12-M04, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 11/08/2021, Last updated: 01/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, baricitinib
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Dermatology
PIP number: EMEA-001220-PIP03-16-M02, Route(s) of administration: Oral use, Pharmaceutical form(s): Oral suspension, Tablet
Decision date: 11/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Feraccru, ferric maltol
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001195-PIP01-11-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard, Oral suspension
Decision date: 11/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): procaine (hydrochloride), xylitol, potassium chloride, magnesium sulfate heptahydrate
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Other
PIP number: EMEA-001171-PIP01-11-M02, Route(s) of administration: Intracoronary use, Pharmaceutical form(s): Solution for injection
Decision date: 11/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Heplisav B, Hepatitis B (rDNA) surface antigen adjuvanted
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Vaccines
PIP number: EMEA-001127-PIP02-11-M01, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Solution for injection
Decision date: 11/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Uptravi, Selexipag
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Other
PIP number: EMEA-000997-PIP01-10-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Tablet
Decision date: 13/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Exparel liposomal, bupivacaine
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Pain
PIP number: EMEA-000877-PIP03-17-M03, Route(s) of administration: Perineural use, Infiltration use, Pharmaceutical form(s): Suspension for injection, Prolonged-release dispersion for injection
Decision date: 09/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Brintellix, Vortioxetine
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Psychiatry
PIP number: EMEA-000455-PIP02-10-M08, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral liquid dosage form
Decision date: 13/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Vimpat, lacosamide
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-000402-PIP03-17-M05, Route(s) of administration: Oral use, Intravenous use, Pharmaceutical form(s): Film-coated tablet, Solution for infusion, Syrup
Decision date: 20/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Entresto, sacubitril, valsartan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000316-PIP02-11-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate solid oral dosage form
Decision date: 13/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Ocrevus, ocrelizumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-000310-PIP03-10-M05, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 13/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): RoActemra, tocilizumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-000309-PIP04-17-M03, Route(s) of administration: Subcutaneous use, Intravenous use, Pharmaceutical form(s): Solution for injection, Concentrate for solution for infusion
Decision date: 13/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Saxenda, liraglutide
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-000128-PIP02-09-M04, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 13/08/2021, Last updated: 31/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Elafibranor
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-001857-PIP02-20, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 12/08/2020, Last updated: 10/08/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cometriq, cabozantinib
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-001143-PIP01-11-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Age-appropriate oral solid dosage form, Tablet, Capsule, hard
Decision date: 19/07/2021, Last updated: 25/07/2022, Compliance check: X